Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases.
BACKGROUND
Recent advances in image guidance and stereotactic body radiotherapy (SBRT) have resulted in unprecedented local control for spinal metastases of all histologies. However, little is known about early imaging biomarkers of local control.


OBJECTIVE
This study aimed to identify early magnetic resonance imaging (MRI) biomarkers to predict local control after SBRT for patients with sarcoma spine metastases.


METHODS
This study used a retrospective case series at a large tertiary cancer center.


METHODS
From 2011 to 2014, 9 consecutive patients with 12 metastatic sarcoma lesions to the spine were treated with SBRT and underwent evaluation with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) both pre- and post-SBRT.


METHODS
Changes in perfusion metrics, including the wash-in rate constant (Ktrans), plasma volume (Vp), composite multiparametric magnetic resonance imaging (mpMRI) score, bi-dimensional tumor size, and a graded response assessment were performed and correlated to local control.


METHODS
All measurements were independent and blinded by two neuroradiologists. R2 statistics were performed to document correlation, and two-tailed t tests were used to compare groups. p<.05 was deemed statistically significant.


RESULTS
The median time from SBRT until posttreatment MRI was 57 days. Local failure developed in one lesion (8.3%) 10 months after SBRT. The Vp mean, Ktrans mean, Vp max, and Ktrans max were significantly decreased post-SBRT as compared with pre-SBRT (58.7%, 63.2%, 59.0%, and 55.2%; all p-values <.05). Bi-dimensional tumor measurements demonstrated an average increase in size across the cohort, and 50%, 25%, and 25% of the treated lesions demonstrated features of "worsening," "no change," or "improvement," respectively, by both radiologists' graded impressions. There was good inter-reader reliability for both size and subjective disease response scores (R2=0.84). The mpMRI score had 100% accuracy in predicting local control at time of last follow-up. There was no apparent correlation with size changes compared with the mpMRI score change post-SBRT (R2=0.026).


CONCLUSIONS
We report the first analysis on the utility of DCE-MRI for metastatic sarcoma spine metastases treated with SBRT. We demonstrate that early assessment at 2 months post-SBRT using size and subjective neuroradiology impressions is insufficient to judge ultimate disease progression, and that a combination of perfusion parameters provides excellent correlation to local control.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA; Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI 48109. Electronic address: sprattda@med.umich.edu.
Daniel E
DE
Spratt
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Julio
J
Arevalo-Perez
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Jonathan E
JE
Leeman
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Naamit K
NK
Gerber
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA; Department of Radiation Oncology, UT Southwestern, 2001 Inwood Rd, Dallas, TX 75235.
Michael
M
Folkert
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Neil K
NK
Taunk
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Kaled M
KM
Alektiar
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Sasan
S
Karimi
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
John K
JK
Lyo
Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
William D
WD
Tap
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Mark H
MH
Bilsky
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Ilya
I
Laufer
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Yoshiya
Y
Yamada
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 22, New York, NY 10065, USA.
Joseph R
JR
Osborne
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003287:Contrast Media; D018450:Disease Progression; D005260:Female; D005354:Fibrosarcoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D006393:Hemangiopericytoma / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery; D006801:Humans; D007890:Leiomyosarcoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D018208:Liposarcoma, Myxoid / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016634:Radiosurgery; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000000981:diagnostic imaging / Q000556:secondary / Q000601:surgery; D012509:Sarcoma / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary / Q000601:surgery
D003287:Contrast Media
Imaging; MRI; Metastases; Radiotherapy; Sarcoma; Spine; Stereotactic radiotherapy